6292-71-3

Basic information

• Product Name: 4-METHOXYBENZALDEHYDE SEMICARBAZONE 97
• Synonyms: 4-METHOXYBENZALDEHYDE SEMICARBAZONE 97
• CAS NO: 6292-71-3
• Molecular Formula: C₉H₁₁N₃O₂
• Molecular Weight: 193.205
• Mol File: 6292-71-3.mol
• Article Data: 28

Chemical Properties

• Melting Point: 203-207 °C(lit.)
• Appearance: /
• Density: 1.22g/cm³
• Refractive Index: 1.565
• CAS DataBase Reference: 4-METHOXYBENZALDEHYDE SEMICARBAZONE 97(CAS DataBase Reference)
• NIST Chemistry Reference: 4-METHOXYBENZALDEHYDE SEMICARBAZONE 97(6292-71-3)
• EPA Substance Registry System: 4-METHOXYBENZALDEHYDE SEMICARBAZONE 97(6292-71-3)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• Hazardous Substances Data: 6292-71-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H11N3O2/c1-14-8-4-2-7(3-5-8)6-11-12-9(10)13/h2-6H,1H3,(H3,10,12,13)

Upstream product

• 563-41-7 semicarbazide hydrochloride 
• 123-11-5 4-methoxy-benzaldehyde 
• 4334-74-1 4-methoxybenzylidene thiosemicarbazone 
• 7722-84-1 dihydrogen peroxide 
• 79-19-6 thiosemicarbazide 
• 637-69-4 4-Methoxystyrene 
• 4426-72-6 hydrazine carboxamide 

Downstream Products

• 110-21-4 hydrazodicarboxamide 
• 622-73-1 4-methoxybenzaldehydephenylhydrazone 
• 128786-00-5 3-{[1-(4-Methoxy-phenyl)-meth-(E)-ylidene]-amino}-imidazolidine-2,4-dione 
• 104-93-8 p-methylanizole 
• 89335-21-7 2-{[5-(4-methoxyphenyl)-1,3,5-oxadiazol-2-yl]imino}-4-thiazolidinone 
• 59940-09-9 2-chloro-N-[5-(4-methoxyphenyl)-[1,3,4]oxadiazol-2-yl]acetamide 
• 80691-89-0 2-(4-Methoxy-phenyl)-benzo[4,5]imidazo[2,3-b][1,3,4]oxadiazol-6-ol 
• 62036-07-1 3-ethoxy-5-(4-methoxyphenyl)-4H-1,2,4-triazole 
• 33199-43-8 C₉H₉N₃O₂ 
• 1261138-31-1 C₂₃H₁₆N₄O₃ 

Relevant articles and documents

Synthesis and anticonvulsant evaluation of indoline derivatives of functionalized aryloxadiazole amine and benzothiazole acetamide

A series of N-(substituted benzothiazole-2-yl)-2-(2,3-dioxoindolin-1-yl)acetamide (4a-i) and substituted-[3-((5-phenyl-1,3,4-oxadiazole-2-yl)imino)indolene-2-one] (5a-f) were designed, synthesized fulfilling the structural requirement of pharmacophore and evaluated for anticonvulsant activities using maximal electroshock test (MES), subcutaneous pentylenetetrazole (scPTZ) seizures and neurotoxicity by motor impairment model in mice. The most active compoundN-(5-chlorobenzo[d]thiazol-2-yl)-2-(2,3-dioxoindolin-1-yl)acetamide (4a) has shown significant anticonvulsant activity against both MES and scPTZ screens and emerged as most effective anticonvulsant compound with median dose of 35.7 mg/kg (MES ED50), 88.15 mg/kg (scPTZ ED50) and toxic dose (TD50) was found to be > 500mg/kg. In silico studies including molecular docking study was carried to establish the molecular interaction of potent compound (4a) in both Na+ channel and GABAA receptors. The prediction of pharmacokinetic parameters and distance mapping of compounds were also performed to establish the drug likeness property.

SSAO INHIBITOR

The present invention provides an SSAO inhibitor and an application thereof in preparing a drug for treating a disease related to SSAO. In particular, the present invention provides a compound shown in formula (IV) and a pharmaceutically acceptable salt thereof.

Semicarbazone derivatives as urease inhibitors: Synthesis, biological evaluation, molecular docking studies and in-silico ADME evaluation

A series of hydrazinecarboxamide derivatives were synthesized and examined against urease for their inhibitory activity. Among the series, the 1-(3-fluorobenzylidene)semicarbazide (4a) (IC50 = 0.52 ± 0.45 μM), 4u (IC50 = 1.23 ± 0.32 μM) and 4h (IC50 = 2.22 ± 0.32 μM) were found most potent. Furthermore, the molecular docking study was also performed to demonstrate the binding mode of the active hydrazinecarboxamide with the enzyme, urease. In order to estimate drug likeness of compounds, in silico ADME evaluation was carried out. All compounds exhibited favorable ADME profiles with good predicted oral bioavailability.